Correlation Between Pharvaris and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both Pharvaris and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pharvaris and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pharvaris BV and Dermata Therapeutics, you can compare the effects of market volatilities on Pharvaris and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pharvaris with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pharvaris and Dermata Therapeutics.

Diversification Opportunities for Pharvaris and Dermata Therapeutics

-0.34

Correlation Coefficient

Pharvaris  Dermata Therapeutics

Very good diversification

The 3 months correlation between Pharvaris and Dermata is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Pharvaris BV and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Pharvaris is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pharvaris BV are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Pharvaris i.e., Pharvaris and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Pharvaris and Dermata Therapeutics

Given the investment horizon of 90 days Pharvaris BV is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Pharvaris BV is 1.94 times less risky than Dermata Therapeutics. The stock trades about -0.15 of its potential returns per unit of risk. The Dermata Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  113.00  in Dermata Therapeutics on November 28, 2024 and sell it today you would earn a total of  7.00  from holding Dermata Therapeutics or generate 6.19% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Pharvaris BV  vs.  Dermata Therapeutics

Pharvaris BV

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pharvaris BV has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Dermata Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating primary indicators, Dermata Therapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Pharvaris and Dermata Therapeutics

The main advantage of trading using opposite Pharvaris and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pharvaris position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind Pharvaris BV and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.